9月29日，苏州创新药研究院在苏州生物医药产业园揭牌。中国工程院院士詹启敏，市委副书记、 市长吴庆文，苏州大学党委书记张晓宏、校长张桥，亚盛药业董事长杨大俊，信达生物首席运营官周凯 松出席活动。 吴庆文在致辞时代表苏州市委、市政府对研究院的成立表示祝贺。他说，生物医药是苏州"十年磨 一剑"长期坚守、重点打造的主导产业。成立苏州创新药研究院是苏州持续助推生物医药产业全链条创 新发展的重要举措。希望研究院保持耐心与定力，以创新体制机制统筹链接各类资源，当好技术攻关 的"加速器"、拔尖人才的"孵化器"、成果转化的"连接器"，成为苏州生物医药产业的创新策源地。苏州 将持续优化政策供给，主动靠前服务，营造更好环境，全力支持研究院建设发展。 苏州创新药研究院由苏州市政府、苏州工业园区与苏州大学携手共建，将秉持"企业出题、联合解 题、政府助题"理念，聚焦分子靶向药物、生物药、基因与细胞治疗、AI药物研发等前沿领域，开展有 组织科研和有组织转化，致力于解决头部企业技术攻关和人才培养需求，打造"实验室—企业—医院"三 位一体的创新闭环，推进"政产学研医"深度融合。活动中，研究院与亚盛药业、信达生物企业联合创新 中心先后揭牌，苏 ...

Core Points - The 2025 Policy Address by Hong Kong Chief Executive John Lee emphasizes economic development and aligning with national strategies [1] - Specific measures include accelerating the development of the Northern Metropolis, industrial innovation, and reinforcing Hong Kong's status as an international financial center [1] Development of Northern Metropolis - The Northern Metropolis is identified as a new economic engine for Hong Kong, with plans to establish a "Northern Development Committee" led by John Lee [2] - The government will create dedicated legislation to facilitate the development of the Northern Metropolis, including funding channels for park companies and streamlined cross-border logistics [2] - The first phase of the Hong Kong Science and Technology Innovation Cooperation Zone is complete, with major industries like life sciences and AI tenants moving in [2] Industrial Development and Innovation - Emphasis on artificial intelligence (AI) development, including a HKD 3 billion funding plan to attract international research talent [4] - Plans to establish the "Hong Kong AI Research Institute" by 2026 with a budget of HKD 1 billion to promote AI research and application [4] - The life sciences sector is set to grow, with initiatives to attract pharmaceutical companies for clinical trials and the establishment of an "International Clinical Trial Academy" [5] Reinforcing Hong Kong's Financial Center Status - The government aims to support tech companies in raising funds through the stock market and improve listing mechanisms [6] - Initiatives to enhance the bond market include creating a centralized platform for managing various assets and promoting offshore Chinese government bonds [6][7] - Plans to establish an international gold trading market and enhance commodity trading, including carbon trading [7][8] Stock Market Performance - Following the Policy Address, the Hang Seng Index rose by 1.41%, reaching a new high [9] - The Hong Kong stock market has seen significant recovery in 2025, with the Hang Seng Index up over 33% year-to-date and new stock issuance increasing dramatically [10][11] - The average daily trading volume in the Hong Kong stock market has surged by 118% year-on-year [11]

Core Viewpoint - Via Biotechnology (01873) experienced a significant stock price increase of over 20% following the release of its interim results for the six months ending June 30, 2025, with a reported share price of HKD 2.85 and a trading volume of HKD 49.03 million [1] Financial Performance - The company reported revenue of RMB 832 million, a year-on-year decrease of 15.27% [1] - Shareholder profit attributable to the company was RMB 122 million, reflecting a year-on-year increase of 4.28% [1] - Basic earnings per share were RMB 0.06 [1] - The gross profit margin improved to 40.8%, an increase of 6.3 percentage points compared to the same period last year, attributed to optimization of the Langhua business structure and enhanced operational efficiency in CRO business [1] AI Drug Development - Via Biotechnology has been investing in AI drug development for the past five years, with AI-related orders now accounting for 12% of new signed orders, indicating a growing trend [1] - According to Guojun International, significant transactions in AI drug development (AIDD) have occurred in the last five years, totaling over USD 50 billion [1] - The development of generative AI in pharmaceuticals emphasizes the importance of building leading model barriers over time, with efficiency in model development and training experience being crucial [1] - Collaborations with large pharmaceutical companies in AI research and development create a positive feedback loop in data and model construction, enhancing the competitive moat of leading firms [1]